To continue as a company that contributes broadly to people’s health, we are constantly pursuing the challenge of creating high-value m ビット カジノs that meet medical needs.
For this, in tandem with our in-house drug discovery innovation, we need to expand our development pipeline through in-licensing.
By expanding the development pipeline, stabilizing existing alliances, and acquiring new businesses, we will secure stable earnings and create new business opportunities for the m ビット カジノs business, thereby contributing to its sustainable growth.
We aim to secure six or more in-licensed products during the period of the medium-term business plan “Vision 110 -Stage1-.”
Changing environment(internal and external)
- Advances in digital transformation in medicine
- Increasing sophistication and difficulty of drug discovery
- Diversification and complexity of drug discovery modalities
- Depleted development pipeline
Opportunities
- Expansion of technological innovation through open innovation
- Increase in opportunities to collaborate with partners from different industries
- Significant increase in capital and personnel
Risks
- Surging investments in in-licensing contracts
- Intensified competition in project acquisition
Medium-term business plan
Vision 110 –Stage1– initiatives
Business strategyExpanding development pipeline through in-licensing
Significantly strengthen our ability to acquire in-licensed products
- Expand modalities and disease areas targeted for in-licensing and pursue wide-ranging in-licensing activities
- Increase in-licensing investments and boost investments in organizational reforms and human resources
Promote development of digital therapeutics (DTx)
- Develop a therapeutic application in the field of otolaryngology
Initiatives under the medium-term business plan
Search and evaluate through organizational reforms and deployment of human resources
To achieve the objectives of “Stage1” for in-licensing search and evaluation, we are always considering multiple projects simultaneously, making it important to work closely with relevant departments to proceed with speedy and accurate evaluations.
For this, we have established the Licensing Department (licensing activities) and the Alliance Department (contract negotiations and management of alliances) within the Business Development Headquarters, creating a “one-stop” in-licensing structure for everything from exploration to evaluation, negotiation of terms and conditions, and conclusion of contracts.
Making full use of this strengthened organization and functionality as well as our human resources, we will strive to maximize both the volume and the quality of activities to acquire in-licensing projects.
Expand in-licensing target modalities and disease fields
To broaden our development pipeline, we need to expand target modalities and disease fields and pursue in-licensing initiatives in a wide range of areas.
In addition to small molecule drug discovery, we will work to acquire at an early date development candidates that will enable us to demonstrate our strengths in new modalities and disease fields outside our franchise customer (FC) field (respiratory, otolaryngology, and urology), as well as obtain in-licensed products with viable commercial prospects.
With competition to acquire promising m ビット カジノ candidates intensifying, we will significantly increase our investment in in-licensed product acquisition.
This approach will lead to m ビット カジノs that contribute to people’s health, and we will tirelessly pursue in-licensing activities.
Promote DTx development
Amid advances in recent years in digital transformation (DX) in the medical field, we have also taken on the challenge of engaging in R&D on digital therapeutics (DTx).
In November 2022, we concluded an agreement with SUSMED, Inc. to conduct joint R&D and sales related to DTx as software for medical devices.
Pursuing proactive partnering activities
The Alliance Department and the Licensing Department under the Business Development Headquarters works closely with other relevant departments to pursue proactive partnering activities.
We have worked to expand our development pipeline by concluding an agreement in September 2020 with ASKA Pharmaceutical Co., Ltd. for the joint development and sales of AKP-009, a benign prostatic hyperplasia treatment, by finalizing a licensing agreement in January 2020 with aTyr Pharma, Inc. of the United States for the interstitial lung disease treatment KRP-R120, and by reaching an agreement in April 2021 with MSD K.K. for the exclusive distribution rights in Japan for Lyfnua (launched in April 2022), a treatment for intractable chronic cough.
Our existing businesses maintain alliances with several dozen companies in Japan and overseas, as we work to create new businesses through proactive partnering activities.
Promoting global out-licensing activities
We are proactively pursuing out-licensing activities with global companies to maximize the value of our proprietary products.
In October 2020, we concluded an agreement for the transfer of intellectual property rights for the immunomodulator KRP-203 to Priothera Limited of Ireland; in March 2021, we signed a licensing agreement with Eisai Co., Ltd. for the development and sales of the overactive bladder treatment Vibegron (sales name in Japan: Beova) in four ASEAN countries; and in March 2023, we signed a licensing agreement with Sumitomo Pharma Co., Ltd. For development, manufacturing, and sales of Vibegron in Taiwan and other regions.
Going forward, we will continue to engage in proactive partnering activities worldwide to quickly roll out our own products in various countries and regions to provide high-value pharmaceutical products that contribute to people’s health.
Partnering with Companies in Japan and Overseas
